---
title: "BRIEF: Hangzhou Diagens doubles in Hong Kong debut"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/281063957.md"
description: "The Hong Kong-listed medical device manufacturer Hangzhou Dian Biotechnology Co., Ltd. saw its stock price double on its first trading day, becoming a highlight among the four companies newly listed in the vibrant IPO market in Hong Kong this year. Dian raised approximately HKD 720 million (about USD 92 million) in net proceeds by selling around 8 million shares at a price of HKD 99 per share. The allocation for local Hong Kong investors was oversubscribed more than 1,000 times, while the international portion was oversubscribed 2.45 times. The stock opened at more than double the IPO price and maintained most of its gains during afternoon trading, rising by 117%, with a market capitalization of approximately HKD 19.1 billion"
datetime: "2026-03-30T18:05:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281063957.md)
  - [en](https://longbridge.com/en/news/281063957.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281063957.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/281063957.md) | [繁體中文](https://longbridge.com/zh-HK/news/281063957.md)


# BRIEF: Hangzhou Diagens doubles in Hong Kong debut

Shares of medical device maker **Hangzhou Diagens Biotechnology Co. Ltd.** (2526.HK) more than doubled in their Hong Kong trading debut on Monday, as Hong Kong’s hot IPO market recorded four new listings in a single day – the most this year.

Diagens raised about HK$720 million ($92 million) in net proceeds by **selling** about 8 million shares for HK$99 each. The portion of the listing for local Hong Kong investors was more than 1,000 times oversubscribed, while the international portion was 2.45 times oversubscribed.

The stock opened at more than double the IPO price, and held on to most of the gains to trade at HK$215 midway through the afternoon session, up 117%. That gave the company a market value of about HK$19.1 billion.

Diagens’ revenue rose more than fivefold to 111.6 million yuan ($16.1 million) in the first nine months of last year from 19.6 million yuan in the same period a year earlier. Its loss over that time narrowed to 36.3 million yuan from 50.4 million yuan.

Diagens was one of four companies to make their trading debuts on Monday, alongside Shandong Extreme Vision Technology Co Ltd. (6636.HK), Guangdong Huayan Robotics Co. Ltd. (1021.HK) and Epiworld International Co. Ltd. (2726.HK). All four stocks were up in Monday afternoon trading in Hong Kong. The four new listings marked a high for new debuts on a single day since six stocks made their trading debut on Dec. 30 last year. Nearly 40 companies have listed in Hong Kong so far this year, even though the first quarter is typically a slow period due to the Lunar New Year holiday.

_By Doug Young_

_To subscribe to Bamboo Works weekly free newsletter, click here_

### 相关股票

- [DIAGENS-B (02526.HK)](https://longbridge.com/zh-CN/quote/02526.HK.md)

## 相关资讯与研究

- [Chinese company to use AI-powered testing to boost profits and fast-track IVF](https://longbridge.com/zh-CN/news/280950532.md)
- [Hong Kong misses March target for first stablecoin licenses](https://longbridge.com/zh-CN/news/281399859.md)
- [Hong Kong tightens grip on IPO crown as filings surge and pipeline grows](https://longbridge.com/zh-CN/news/281344405.md)
- [Breathing fire: Manycore first of the ‘Six Little Dragons’ to near Hong Kong IPO](https://longbridge.com/zh-CN/news/281036284.md)
- [InnoCare Hits Profit Milestone, Relative Undervaluation Points To Stock Upside](https://longbridge.com/zh-CN/news/280994733.md)